oncnursingnews16h
Dorothy N. Pierce
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews1d
Adding Lenvatinib/Pembrolizumab to TACE Extends PFS in Unresectable Liver Cancer
The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...
oncnursingnews2d
Investigational Nasal Spray May Improve Symptoms in Cancer Cachexia
Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.
oncnursingnews2d
FDA Approves Acalabrutinib-Based Regimen for Previously Treated MCL
The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle ...
oncnursingnews2d
Sotorasib Plus Panitumumab Receives FDA Approval for KRAS G12C–Mutated Colorectal Cancer
The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) ...
oncnursingnews2d
Drug Toxicity May Drive Early Niraparib Discontinuation in Ovarian Cancer
Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized ...
oncnursingnews2d
Bridget Hoyt
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews3dOpinion
Opinion: Subcutaneous Nivolumab Offers an Effective Alternative to Intravenous Administration
Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...
oncnursingnews4d
A Critical Step: What Nurses Need to Know About HRD Testing for Advanced Ovarian Cancer
As integral members of the care team, it’s imperative that nurses understand the role of tumor testing for women with advanced ovarian cancer. Approximately 50% of patients with advanced ovarian ...